BACKGROUND: A family history of liver cancer increases the risk of developing hepatocellular carcinoma (HCC) by 2-fold to 10-fold among patients with chronic hepatitis B virus (HBV). Previous genome-wide association studies have identified many possible susceptible loci associated with sporadic HBV-related HCC. However, despite family history being a well-known risk factor for HBVrelated HCC, to the authors' knowledge its genetic mechanisms and associating loci remain largely unknown or unexplored, most likely due to the relative rarity of familial HCC and the difficulty of sample collection. METHODS: The authors conducted a genomewide association study with 139 male cases with familial HBV-related HCC and 139 non-HCC male controls with chronic HBV. The results were corroborated further with an independent cohort of 101 patients with familial HBV-related HCC and comparison with both the 1000 Genomes Project and the Taiwan Biobank. RESULTS: A total of 51 risk single-nucleotide polymorphisms (P1E-04) were identified in the association analyses, which included 2 clusters of associated single-nucleotide polymorphisms and haplotypes at 1q25. FOXN1] ). Both the GLUL and SLC13A2/FOXN1 haplotypes have large effect sizes and were found to be different from those found from genome-wide association studies of sporadic HCCs. CONCLUSIONS: To the authors' knowledge, the current study is the first genome-wide association study to identify genetic factors for familial HBV-related HCC. The results identified 2 large effect susceptible haplotypes located at GLUL and SLC13A2/FOXN1. The current study findings also suggest different genetic susceptibility between familial and sporadic HBV-related HCC. Cancer 2017;123:3966-76. V C 2017 American Cancer Society.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, ranking fifth among human cancers. Chronic viral hepatitis, either hepatitis B virus (HBV) or hepatitis C virus, accounts for the majority of etiology along with metabolic fatty liver and alcoholic liver diseases. Additional risk factors include age, male sex, familial history, smoking, and diabetes. [1] [2] [3] Greater than 70% of patients with HCC in Asia have been chronically infected with HBV. 4, 5 For those carrying chronic HBV infection, the lifetime risk of developing HCC is approximately 10% to 30%. The importance of host genetic factors and family history have been proposed in recent studies because approximately 3% to 5% of HBV-related HCC demonstrate familial HCC aggregation. 6 Multifactorial inheritance could result in an increased HCC risk in those with a family history of liver cancer and an earlier age at onset. 7 Conversely, patients with sporadic cancer typically have a later age at onset, likely due to nonhereditary causes. From this point of view, HCC can be classified by the patient's family history into familial and sporadic cases, with greater than 80% of HCC cases belonging to the latter. 1, 6 HCC with a family history of 1 close relatives (first-degree or second-degree relatives) with HCC is categorized as familial HCC, whereas sporadic HCC has no HCC-related family history within close relatives. Individuals with a family history of HCC have an increased overall risk of developing HCC compared with those without a family history. 1 The genetic pattern between familial and sporadic HCC cases are distinctly different. 3 Familial HCC cases may have common genetic backgrounds or hereditary genetic factors, whereas sporadic HCC cases most likely result from nonhereditary factors. Several recent genome-wide association studies (GWAS) of HBV-related HCC have led to the identification of multiple HCC susceptible loci, albeit with poor consistency. [8] [9] [10] [11] The human leukocyte antigen (HLA)-DQ gene cluster was the only locus identified by separate studies, whereas VEPH1, FZD4, L3MBTL4, GRIK1, KIF1B, and STAT4) were each only identified by a single GWAS. However, the HCC cases used in these GWAS did not discriminate between familial and sporadic HCC cases and therefore are presumably mainly sporadic HCC cases. 12 Previous familial HCC studies used methods including protein mass spectrometry, clinical and pathological characteristic association, and association analysis of a limited number of single-nucleotide polymorphisms (SNPs). [13] [14] [15] Specifically, Shih et al performed an association analysis similar to the methods of GWAS but with a short coverage range of only 67 SNPs, of which they identified 2 associated haplotype blocks within 3 0 -phosphoadenosine 5 0 -phosphosulfate synthase 1 (PAPSS1), albeit with low significance (P7.5E-3). 15 Therefore, to our knowledge, the specific genetic factors correlated with familial HCC have not yet been studied by GWAS, most likely due to the difficulty in collecting sufficient familial HCC cases. To overcome this barrier, we recruited 139 familial HCC cases in Taiwan over the course of 10 years, and then performed a genome-wide association analysis to search for susceptible loci for familial HBV-related HCC. The results were corroborated further with an independent cohort of 101 patients with familial HBV-related HCC and comparison with both the 1000 Genomes Project and the Taiwan Biobank (TWB). 16, 17 
MATERIALS AND METHODS

Study Subjects
We performed genome-wide scanning using 2 sets of study subjects from different sources. All study subjects were positive for HBV surface antigen (HBsAg). We specifically selected for patients with 1 first-degree relatives with HCC.
The first set involved a case-control study design, which was used for association analysis for SNP discovery. Case patients include 139 male HCC cases who were selected among 5968 patients with HCC who were consecutively recruited from 1997 through 2007 in a multicenter study designed to explore genetic and environmental determinants for HCC, as previously described. 18 The mean age at onset in this case series was 52.7 6 7.8 years, and 23% of the patients had 2 affected first-degree relatives. Control subjects were 139 male, unrelated individuals selected among non-HCC HBV carriers without a first-degree family history of HCC, who participated in a published cohort study of 4841 HBsAg carriers. 18 Control subjects were frequency matched to the case patients by year of birth (within 10 years). This study was approved by the research ethics committee at the College of Public Health of National Taiwan University, and all study subjects provided informed consent.
To further explore the prevalence of identified SNPs in HCCs from a family with a high degree of familial aggregation of HCC, we conducted genome-wide scanning in a second series of HCC cases consisting of 101 cases of familial HBV-related HCC (including 79 male and 22 female cases), each with 2 first-degree relatives affected with HCC, and the mean age at the time of diagnosis of these cases was 56.5 6 9.6 years. The second series of cases was drawn from the Taiwan Liver Cancer Network at National Health Research Institutes in collaboration with 5 medical centers across northern (National Taiwan University Hospital and Chang Gung Memorial Hospital Linko Branch), central (Taichung Veteran General Hospital), and southern (Chang Gung Memorial Hospital Kaohsiung Branch and Kaohsiung Veteran General Hospital) Taiwan. 19 
Comparison With External Data Sets
To further confirm identified SNP and haplotype results of HBV-related familial HCC, we compared SNP and haplotype frequencies with those of the 1000 Genome Project and the TWB. SNP and haplotype frequencies of the 1000 Genome Project were calculated using the Han Chinese in Beijing, China (CHB) and Han Chinese South (CHS) data sets, and SNP frequencies were derived from the TWB general population data set.
GWAS Genotyping
Genome-wide genotyping analysis was performed at the National Center for Genome Medicine of Academia Sinica using the Axiom-Taiwan Biobank Array Plate (TWB chip; Affymetrix Inc, Santa Clara, California). 17 The TWB chip, which consists of 653,291 SNPs, was specifically customized for the Taiwanese population, who mainly are of the Han-Chinese lineage, by including SNPs with detected polymorphisms in Taiwanese-based genotyping results from the Axiom Genome-Wide CHB 1 Array plate (Affymetrix Inc). SNPs from ancestry information panels, GWAS and cancer studies, and pharmacogenetic arrays also were incorporated into the TWB chip. Data sets were excluded if the SNP call rates were <95%. SNPs were excluded if the minor allele frequency (MAF) GLUL Identified by GWAS of Familial HCC/Lin et al
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October 15, 2017 in the population was <5%. Hardy-Weinberg equilibrium (HWE) analysis was performed for each SNP.
GWAS Analyses
GWAS analyses were performed using the PLINK opensource whole-genome association analysis toolset (version 1.07; http://pngu.mgh.harvard.edu/purcell/plink/) with both allelic and haplotype analyses using the allele frequency-based default model. 20 Manhattan plots were generated using the Integrative Genomics Viewer. 21 Cluster-specific analyses were performed with Perl scripts. Gene-specific analyses were performed with Versatile Gene-based Association Study (VEGAS). 22 
RESULTS
We performed a genome-wide SNP analysis among 139 familial HBV-related HCC cases and 139 HBV controls to identify susceptibility loci for familial HBV-related HCC (Table 1) . After the exclusion of data sets with SNP call rates <0.95 and SNPs with call rates <0.95 or a MAF <0.05, we obtained genotyping data for 641,398 SNPs in 139 cases and 139 controls (Fig. 1a) . No population stratification was suggested from quantile-quantile plot results (genomic inflation factor k, 1.01). Association analysis identified 51 common SNPs with significant associations with familial HBV-related HCC (Table 2 ) (P1E-04). Nearly one-half (25/51; P 5.49) of the identified SNPs were intragenic or within 5 kilobases (kb) of the nearest gene, which is similar to that of the TWB chip (301,307/ 653,291; P 5.46).
Previous studies have suggested that gene-specific or cluster-specific analyses of GWAS data sets may identify additional variants not detected by SNP-specific analyses. 23, 24 Further analyses of association results revealed 2 SNP clusters, each consisting of 3 closely located SNPs ( (Fig. 1) . Genebased association analysis using VEGAS also showed TEDDM1 (P 5 2.20E-05) and GLUL (P 5 3.30E-05) to be the top 2 genes significantly associated with familial HBV-related HCC (Table 4 ). LINC00272 and RGSL1 were not included in the reference database of VEGAS.
The plateau-like distribution of the significance association of the SNPs in the GLUL SNP cluster suggested that no single SNP was solely accountable for the observed association (Fig. 1b) . Haplotype analysis of the GLUL SNP cluster suggested that the first 14 SNPs of the cluster constituted a linkage disequilibrium (LD) block (LD1), and the last 2 SNPs belonged to another LD block (LD2) ( Table 5 ). LD1 spans GLUL/TEDDM1/ LINC00272 and has 2 main haplotypes, one of which consists of all 14 major SNP alleles (LD1M) and the other consists of all 14 minor SNP alleles (LD1m). LD2 spans LINC00272/RGSL1 and also consists of haplotypes with all major (LD2M) or minor (LD2m) SNP alleles. Haplotype association analysis suggested that LD1M, LD1m, LD2M, and LD2m were individually associated with familial HBV-related HCC (P values of 2.62E-04, 1.18E-04, 1.03E-03, and 4.09E-04, respectively), whereas haplotype combinations of LD1M/LD2m (P 5 5.98E-04) and LD1m/LD2M (P 5 2.20E-04) both demonstrated a significant association. The odds ratios (ORs) of each minor allele haplotype (LD1m and LD2m) ( Table 5) were consistent with their corresponding minor allele SNPs (Table 3 ). These results suggest that LD1m was associated with a greater risk of developing familial HBVrelated HCC, whereas LD2m was associated with a decreased risk of familial HBV-related HCC. All 16 SNPs of the GLUL SNP cluster did not deviate from the HWE analysis in either the case or control data sets.
The GLUL SNP cluster allele and haplotype frequencies were consistent with those of the independent familial HBV-related HCC case cohort (79 males and 22 females) (Table 3) . Furthermore, we compared the allele and haplotype frequencies with the 1000 Genomes Project (CHB and CHS subpopulations) and the TWB. The allele frequency patterns were different between the LD1 and LD2 SNPs. The LD1 SNP allele frequencies for both the CHB and CHS male subpopulations were more similar to those of the case cohort (average frequency difference [FD], 1.5%) compared with the control cohort (average FD, 11.6%), whereas the LD2 SNP frequencies for the CHB and CHS male subpopulations were intermediate between the case and control cohorts. TWB SNP frequencies were intermediate between the case and control cohorts for both the LD1 and LD2 SNPs. Haplotype frequencies for LD1, LD2, and LD1/LD2 were consistent between the 2 case cohorts (FD, 0.2% to approximately 2.8%) and also were similar to the CHS or CHB male subpopulations but with a greater FD (0.3% to approximately 13.9%). Haplotype information was unavailable for the TWB. These results suggest the possibility of 2 separate susceptibility loci within the GLUL cluster (LD1 and LD2), and the signals of either loci could not be attributed to any particular SNP but rather to the haplotypes as a whole.
It is interesting to note that our control cohort had a different HBsAg status from the sampled populations of the 1000 Genomes Project and the TWB. The individuals in the control cohort analyzed in the current study were all positive for HBsAg, whereas the 1000 Genomes Project and the TWB were sampled from their respective general populations, which presumably have a low prevalence of chronic HBV infection. 25, 26 The second SNP cluster included 3 SNPs (rs7406210, rs9303616, and rs4332786) mapped to 17q11.2 located in the intergenic region between solute carrier family 13 member 2 (SLC13A2) and forkhead box N1 (FOXN1) ( Table 3) . Gene-based VEGAS association analysis results demonstrated both SCL13A2 and FOXN1 to be among the top 7 highly associated genes (Table 4) . Haplotype analysis suggested the presence of a LD block (LD3) ( Table 5 ). Similar to LD1 and LD2, the 2 main haplotypes consisted of all major SNP alleles (LD3M) or all minor SNP alleles (LD3m), with frequencies of 72% and 23%, respectively, in the case cohort, and 54% and 38%, respectively, in the control cohort. The allele frequencies of the only common LD3 SNP, rs4332786, between the familial HBV-related HCC case cohort and the independent case cohort were slightly different. The MAF of rs4332786 was higher in the second case cohort by nearly 12%. Unlike the GLUL cluster, the allele frequencies from the CHS, CHB, and TWB data sets were more similar to those of the control cohort than the case cohort. Haplotype frequencies indicated significant discrepancies between the case cohort and when compared with reference data sets. Although LD3M or LD3m were predicted in >92% of genotyped samples in the current study cohort, they constituted <2% and 8%, respectively, in the CHS and CHB male subpopulations. The haplotype with the highest frequency in the CHS and CHB male subpopulations (GGA, LD3GGA) was only predicted in 3% of the cohort data set in the current study. Nonetheless, both LD3M and LD3m were found to be highly associated with familial HBV-related HCC (P 5 2.66E-05 and P 5 8.21E-05, respectively). Similar to the GLUL SNP cluster, the ORs were consistent between the haplotypes and their respective SNPs. These results suggest that LD3M and LD3m were associated with an increased and decreased risk of familial HBV-related HCC, respectively. All 3 SNPs followed HWE. Therefore, the SLC13A2 cluster might contain another susceptibility locus with a haplotype-based signal. The SNP with the highest association with familial HBV-related HCC was mapped to 8p22 located within DLC1 (rs77236434; P 5 3.64E-07 [OR, 9.87]) ( Table  3 ). The MAF was 0.13 in the current study case cohort but was rarely observed in our control cohorts (MAF, 0.01). The extremely rare MAF of the control cohort was consistent with those of the 1000 Genomes Project and the TWB (MAFs of 0.05 and 0.06, respectively, for the CHS male subpopulation and the TWB, respectively). No other neighboring SNPs were found to be associated with familial HBV-related HCC (P1E-04). rs77236434 followed HWE in the case cohorts (P 5 .02), but significantly deviated from HWE in both the control cohorts (P 5 8.58E-10) and the overall data set (P 5 1.57E-13), further suggesting that this SNP might represent a recently derived variation genetically associated with an increased risk of familial HBV-related HCC. 27 To our knowledge, there have been 4 previous GWAS for HBV-related HCC. [8] [9] [10] [11] 28 Previous GWAS did not classify HCC cases according to family history, and presumably the majority of their cases were sporadic HBVrelated HCC. Among the total combined 9 SNPs identified as being strongly associated with HBV-related HCC, only rs7574865, which is located within STAT4, was found to be significantly associated with familial HBV-related HCC in the GWAS data in the current study (P1E-04) ( Table 6) . [8] [9] [10] [11] Both rs9272105 and rs9275319 were located within the HLA-DQ gene cluster and identified from different GWAS studies, but no evidence of an association with familial HBV-related HCC was found for the HLA-DQ gene cluster region in the current study. The GWAS data in the current study identified an SNP, rs3097651, that was significantly associated with familial HBV-related HCC located near major histocompatibility complex human leukocyte antigen class II DP beta 1 (HLA-DPB1) and 400 kb downstream of the HLA-DQ cluster region. The HLA-DPA1/HLA-DPB1 region includes another 76 SNPs associated with familial HBVrelated HCC (P1E-03), which although not meeting our criteria for an associated SNP cluster (3 significantly associated SNPs; P1E-04) still suggests the potential presence of a susceptibility locus (Fig. 2) . No significant association was found with familial HBV-related HCC at the PAPSS1 gene region previously identified by Shih et al. 15 
DISCUSSION
We reported 2 SNP clusters associated with familial HBV-related HCC in the current study. The first SNP cluster overlaps the entire GLUL gene, which is downstream of the Wnt/b-catenin signaling pathway and overly expressed in HCC. [29] [30] [31] Increased GLUL expression has been reported to elevate glutamine levels and promote de novo nucleotide biosynthesis, whereas GLUL inhibition decreases nitrogen enrichment into nucleotides and results in suppressed hepatomegaly and liver cancer cell growth. 32 The GLUL cluster also spans TEDDM1, LINC00272, and RGSL1. TEDDM1 is a transmembrane epididymal protein predominately expressed in the epididymis and reportedly associated with signaling pathways involved in early sperm maturation, whereas LINC00272 is a non-protein-coding RNA and RGSL1 is involved in the G-protein signaling regulation with a suggested role in prostate carcinogenesis. 33, 34 The second SNP cluster spans the 3 0 end of SLC13A2 and is located 15 kb upstream of FOXN1. SLC13A2 is a sodiumcoupled citrate transporter of the solute carrier (SLC) group. 35 Although to our knowledge no interactions with viral pathogens have been reported, SLC13A2 as a membrane transporter still possesses the potential to be an alternative viral entry point during infection. Most notably, SLC10A1, or NTCP, is a sodium taurocholate cotransporter also belonging to the solute carrier group that has been reported to interact with the pre-S1 receptor binding domain of HBV and is involved in HBV infection. 36 In addition, FOXN1 is a transcription factor responsible for the initiation and maintenance of differentiated thymic epithelial cells and is essential for maintaining a functional immune system. 37, 38 Familial cancer cases are observed at low frequencies compared with sporadic cancer cases, and this rarity is one of the main impediments for familial-based studies, resulting in lengthy recruitment for a sizable quantity of cases as well as small sample sizes. To our knowledge, only 6 of the total 2742 GWAS listed in the GWAS Catalog were familial-based studies, of which familial leukemia, prostate, and lung cancer studies with 102, 2511, and 194 familial cases, respectively, were included. [39] [40] [41] [42] [43] [44] [45] Sample size is a crucial factor in association-based studies due to its direct and crucial influence on the power to detect variants of different effect levels. 46 The minimal required sample size needed to achieve adequate statistical power depends on the effect size, MAF, LD, and other various factors. 47 Simulation results by Hong et al have suggested that <100 cases and 100 controls are required for common SNPs with large effects (MAF, 0.2; allelic OR, 2.5), but approximately 2000 cases and controls each are required for rare small-effect SNPs (MAF, 0.05; allelic OR, 1.3) and sample sizes of >10,000 cases and 10,000 controls are required for the detection of SNPs with extremely low frequencies and small effect sizes (MAF <0.01; allelic OR, <1.3). 48 A recent GWAS for the detection of adult human height-associated variants of extreme low frequencies was conducted with >450,000 individuals. 49 Although small-size GWAS have limited power to detect small-effect gene associations, previous studies have consistently demonstrated their potential to identify SNPs with bigger-effect associations (OR, >3; P1E-05). Among the 86 GWAS that have identified large-effect associations, greater than one-half of those studies (46 of 86 studies; 53.5%) had sample sizes of 300 patients. 50 Therefore, the sample size of 139 cases and 139 controls used in the current study was expected to be sufficient for the detection of common SNPs with large effects (MAF, 0.05; OR, 2.5) but lacked statistical power for the detection of rare small-effect SNPs (MAF, <0.05; OR, <1.3). As expected, all but 2 of the 51 risk SNPs identified in the current study had an allelic OR >2 (or <0.5), whereas the remaining 2 risk SNPs were borderline with allelic ORs of 1.99 and 0.51, respectively (Table 2) .
Rare genetic variations of a recent occurrence are another possible genetic mechanism for familial HCC that cannot be easily detected by conventional GWAS. To address this possibility, next-generation sequencing is an alternative method for familial-based cancer studies. [51] [52] [53] GWAS provide a cost-efficient method with which to obtain representative genomic information while sustaining a reasonable sample size. In comparison, although both exome and whole-genome sequencing can provide more complete nucleotide information of targeted regions, their smaller sample sizes due to higher costs results in reduced detection power. Furthermore, analysis methods for GWAS have been well developed over the past 30 years and been proven effective for the identification of numerous important genetic SNPs, whereas next-generation sequencing-based methods have been developed more recently and usually require confirmation with other validated technology. 54 To our knowledge to date, compared with exome 
